As p16 in both cases was less than 5%, it further demonstrates the utility of p16 as a surrogate marker of CDKN2A HD in clinical neuropathology, enabling quicker final diagnosis and circumventing expensive molecular testing. Here, CDKN2A is linked to Huntington disease.